– USA, MA – Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Patrick Gray to the board of directors as an independent director, and the retirement of veteran director Dennis Langer, M.D., J.D.
Mr. Gray will serve as the chairperson of the Audit Committee. Mr. Gray’s appointment is effective immediately.
“As Dicerna continues to grow and mature, our board continues to evolve with the addition of Patrick Gray. Patrick is an accomplished CPA, executive, and director who brings with him extensive industry experience that will help further advance our GalXC-based pipeline and strengthen Dicerna’s position in the promising field of RNAi therapeutics,” said Douglas M. Fambrough, Ph.D., president and CEO.
“We sincerely thank Dennis Langer, who has been on our board since 2007, for his meaningful and numerous contributions over the years. Dennis has played a key role in the growth of our company with his strategic insights, sage counsel, and guidance,” he added.
About Patrick Gray
Mr. Gray currently serves as a member of the board and as chairperson of the audit committee of Tmunity Therapeutics, Inc. He previously served as a member of the board and as the chairperson of the audit committee of Civitas Solutions, Inc., from September 2014 to March 2019, Sancilio Pharmaceuticals Company, Inc., from February 2012 through August 2018, and Datto, Inc., from May 2015 through December 2017. Mr. Gray spent 37 years with PricewaterhouseCoopers LLP (“PwC”) until his retirement in 2009. He is a certified public accountant who spent 25 years as an Audit Partner at PwC. At the time of his retirement, he served as the lead partner for the PwC U.S. firm’s Corporate Governance Group. Prior to that time, Mr. Gray held various other leadership positions within the firm, including leadership of the PwC U.S. High Technology Group. “I am pleased to join the Dicerna board of directors at such an important time for the company as it advances its promising pipeline and engages in strategic partnerships with leading pharmaceutical companies to further extend the potential of its technology,” commented Mr. Gray. “I look forward to helping Dicerna continue to execute on and achieve its goal of developing and delivering innovative and effective therapies for patients in need.”
Mr. Gray holds a B.S. in Economics from The Wharton School, University of Pennsylvania.
About DicernaTM Pharmaceuticals, Inc.
Dicerna™ Pharmaceuticals, Inc. is a biopharmaceutical company using ribonucleic acid (RNA) interference (RNAi) to develop medicines that silence genes that cause disease. The Company’s proprietary GalXC™ technology is being applied to develop potent, selective, and safe RNAi therapies to treat diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna aims to treat disease by addressing the underlying causes of illness with capabilities that extend beyond the liver to address a broad range of diseases, focusing on target genes where connections between gene and disease are well understood and documented. Dicerna intends to discover, develop, and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Eli Lilly and Company (Lilly), Alexion Pharmaceuticals, Inc. (Alexion), and Boehringer Ingelheim International GmbH (BI).
For more information, please visit www.dicerna.com.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.